Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation and Depletion (2021 - 2024)

Historic Depreciation and Depletion for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q4 2024 value amounting to $29000.0.

  • ARS Pharmaceuticals' Depreciation and Depletion rose 14166.67% to $29000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $79000.0, marking a year-over-year increase of 821.92%. This contributed to the annual value of $79000.0 for FY2024, which is 821.92% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Depreciation and Depletion of $29000.0 as of Q4 2024, which was up 14166.67% from $21000.0 recorded in Q3 2024.
  • ARS Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $209000.0 during Q2 2021, with a 5-year trough of -$37000.0 in Q2 2022.
  • Moreover, its 4-year median value for Depreciation and Depletion was $20500.0 (2023), whereas its average is $61625.0.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Depreciation and Depletion crashed by 11770.33% in 2022, and later skyrocketed by 20000.0% in 2023.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Depreciation and Depletion stood at $204000.0 in 2021, then tumbled by 93.14% to $14000.0 in 2022, then fell by 14.29% to $12000.0 in 2023, then skyrocketed by 141.67% to $29000.0 in 2024.
  • Its Depreciation and Depletion was $29000.0 in Q4 2024, compared to $21000.0 in Q3 2024 and $18000.0 in Q2 2024.